Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 193

1.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
2.

Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.

Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y, Sachindra S, Hüser L, Granados K, Gebhardt C, Plass C, Umansky V, Utikal J.

Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32432. [Epub ahead of print]

PMID:
31131878
3.

Pathologist-level classification of histopathological melanoma images with deep neural networks.

Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ.

Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23.

4.

Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance.

Larribère L, Utikal J.

Front Mol Neurosci. 2019 May 1;12:111. doi: 10.3389/fnmol.2019.00111. eCollection 2019. Review.

5.

A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes.

El-Battrawy I, Albers S, Cyganek L, Zhao Z, Lan H, Li X, Xu Q, Kleinsorge M, Huang M, Liao Z, Zhong R, Rudic B, Müller J, Dinkel H, Lang S, Diecke S, Zimmermann WH, Utikal J, Wieland T, Borggrefe M, Zhou X, Akin I.

Europace. 2019 May 18. pii: euz122. doi: 10.1093/europace/euz122. [Epub ahead of print]

PMID:
31106349
6.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

7.

Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes.

Sattler K, El-Battrawy I, Zhao Z, Schrottenberg C, Yücel G, Lan H, Li X, Lang S, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Ravens U, Bieback K, Borggrefe M, Zhou X, Akin I.

Sci Rep. 2019 Apr 4;9(1):5651. doi: 10.1038/s41598-019-42079-z.

8.

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies.

Hüser L, Altevogt P, Utikal J.

Oncotarget. 2019 Mar 1;10(18):1662-1663. doi: 10.18632/oncotarget.26718. eCollection 2019 Mar 1. No abstract available.

9.

Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration.

Schrama D, Sarosi EM, Adam C, Ritter C, Kaemmerer U, Klopocki E, König EM, Utikal J, Becker JC, Houben R.

Int J Cancer. 2019 Aug 15;145(4):1020-1032. doi: 10.1002/ijc.32280. Epub 2019 Apr 4.

PMID:
30873613
10.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8.

11.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Brinker TJ, Hekler A, Hauschild A, Berking C, Schilling B, Enk AH, Haferkamp S, Karoglan A, von Kalle C, Weichenthal M, Sattler E, Schadendorf D, Gaiser MR, Klode J, Utikal JS.

Eur J Cancer. 2019 Apr;111:30-37. doi: 10.1016/j.ejca.2018.12.016. Epub 2019 Feb 22.

12.

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.

Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.

13.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
14.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
15.

Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs.

Dabiri Y, Gama-Brambila RA, Taškova K, Herold K, Reuter S, Adjaye J, Utikal J, Mrowka R, Wang J, Andrade-Navarro MA, Cheng X.

iScience. 2019 Feb 22;12:168-181. doi: 10.1016/j.isci.2019.01.012. Epub 2019 Jan 11.

16.

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis.

Jäger K, Larribère L, Wu H, Weiss C, Gebhardt C, Utikal J.

Cancers (Basel). 2019 Jan 11;11(1). pii: E76. doi: 10.3390/cancers11010076.

17.

Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells.

Thier MC, Hommerding O, Panten J, Pinna R, García-González D, Berger T, Wörsdörfer P, Assenov Y, Scognamiglio R, Przybylla A, Kaschutnig P, Becker L, Milsom MD, Jauch A, Utikal J, Herrmann C, Monyer H, Edenhofer F, Trumpp A.

Cell Stem Cell. 2019 Jan 3;24(1):166-182.e13. doi: 10.1016/j.stem.2018.11.015. Epub 2018 Dec 20.

PMID:
30581079
18.

Tackling malignant melanoma epigenetically: histone lysine methylation.

Orouji E, Utikal J.

Clin Epigenetics. 2018 Nov 22;10(1):145. doi: 10.1186/s13148-018-0583-z. Review.

19.

Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts.

Larribère L, Kuphal S, Sachpekidis C; Sachindra, Hüser L, Bosserhoff A, Utikal J.

Cancers (Basel). 2018 Nov 16;10(11). pii: E451. doi: 10.3390/cancers10110451.

20.

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V.

Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9. Review.

PMID:
30413826

Supplemental Content

Loading ...
Support Center